John Whitesides

1.6k total citations
30 papers, 1.2k citations indexed

About

John Whitesides is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cellular and Molecular Neuroscience. According to data from OpenAlex, John Whitesides has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Psychiatry and Mental health, 21 papers in Pediatrics, Perinatology and Child Health and 11 papers in Cellular and Molecular Neuroscience. Recurrent topics in John Whitesides's work include Epilepsy research and treatment (23 papers), Pharmacological Effects and Toxicity Studies (21 papers) and Neuroscience and Neuropharmacology Research (11 papers). John Whitesides is often cited by papers focused on Epilepsy research and treatment (23 papers), Pharmacological Effects and Toxicity Studies (21 papers) and Neuroscience and Neuropharmacology Research (11 papers). John Whitesides collaborates with scholars based in United States, Germany and United Kingdom. John Whitesides's co-authors include Pavel Klein, Jimmy Schiemann, Martin Johnson, Michael R. Sperling, Christian Brandt, Erwin Surmann, Patrick Kwan, Teresa Gasalla, Babak Boroojerdi and Wei Liang and has published in prestigious journals such as Neurology, Epilepsia and Movement Disorders.

In The Last Decade

John Whitesides

29 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Whitesides United States	17	789	689	494	430	174	30	1.2k
Anna Lisa Luciano Italy	9	290 0.4×	187 0.3×	215 0.4×	353 0.8×	119 0.7×	10	744
PN Patsalos United Kingdom	15	426 0.5×	385 0.6×	197 0.4×	91 0.2×	31 0.2×	32	699
Sami Aboumatar United States	11	494 0.6×	298 0.4×	288 0.6×	58 0.1×	104 0.6×	16	649
Jean Costa Nunes Brazil	16	230 0.3×	125 0.2×	212 0.4×	214 0.5×	177 1.0×	36	724
Dragoslav Sokić Serbia	14	361 0.5×	198 0.3×	119 0.2×	186 0.4×	37 0.2×	57	688
G. J. A. Macphee United Kingdom	12	205 0.3×	198 0.3×	164 0.3×	347 0.8×	35 0.2×	24	746
Peggy O. Clark United States	10	963 1.2×	708 1.0×	370 0.7×	45 0.1×	10 0.1×	13	1.1k
Huiqin Xu China	16	230 0.3×	158 0.2×	121 0.2×	51 0.1×	62 0.4×	53	641
Nikolas Hitiris United Kingdom	10	825 1.0×	655 1.0×	269 0.5×	68 0.2×	7 0.0×	11	952
Andreas Neophytides United States	19	211 0.3×	84 0.1×	231 0.5×	649 1.5×	45 0.3×	42	1.1k

Countries citing papers authored by John Whitesides

Since Specialization

Citations

This map shows the geographic impact of John Whitesides's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Whitesides with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Whitesides more than expected).

Fields of papers citing papers by John Whitesides

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Whitesides. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Whitesides. The network helps show where John Whitesides may publish in the future.

Co-authorship network of co-authors of John Whitesides

This figure shows the co-authorship network connecting the top 25 collaborators of John Whitesides. A scholar is included among the top collaborators of John Whitesides based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Whitesides. John Whitesides is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brodie, Martin J., et al.. (2018). Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program. Epilepsy Research. 145. 55–62. 16 indexed citations

Benbadis, Selim R., et al.. (2018). Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis. Epilepsy & Behavior. 80. 129–134. 11 indexed citations

Klein, Pavel, et al.. (2018). A review of the pharmacology and clinical efficacy of brivaracetam. Clinical Pharmacology Advances and Applications. Volume 10. 1–22. 76 indexed citations

Arnold, Stephan, et al.. (2018). Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies. Epilepsy Research. 141. 73–82. 17 indexed citations

Asadi‐Pooya, Ali A., Michael R. Sperling, Steve Chung, et al.. (2017). Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study. Epilepsy Research. 131. 70–75. 24 indexed citations

Toledo, Manuel, et al.. (2017). Long-term retention rates for antiepileptic drugs: A review of long-term extension studies and comparison with brivaracetam. Epilepsy Research. 138. 53–61. 28 indexed citations

Chung, Steve, et al.. (2016). Efficacy of Brivaracetam (BRV) as Adjunctive Therapy in Partial-Onset (Focal) Seizures Among Patients with Prior Levetiracetam (LEV), Carbamazepine (CBZ), Lamotrigine (LTG), or Topiramate (TPM) Exposure (P2.027). Neurology. 86(16_supplement). 3 indexed citations

Moseley, Brian D., et al.. (2016). Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies. Epilepsy Research. 127. 179–185. 20 indexed citations

Brodie, Martin J., John Whitesides, Jimmy Schiemann, Joseph D’Souza, & Martin Johnson. (2016). Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Research. 127. 114–118. 29 indexed citations

10.

Klein, Pavel, Jimmy Schiemann, Michael R. Sperling, et al.. (2015). A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Adult Patients with Partial-Onset Seizures (S31.009). Neurology. 84(14_supplement). 6 indexed citations

11.

Yacubian, Elza Márcia Targas, et al.. (2015). Efficacy, safety and tolerability of adjunctive Brivaracetam for treatment of partial-onset seizures: post-hoc analysis of results from Latin American patients. Journal of the Neurological Sciences. 357. e160–e160.

12.

Nicholas, Anthony P., Rupam Borgohain, Pedro Chaná, et al.. (2014). A Randomized Study of Rotigotine Dose Response on ‘Off’ Time in Advanced Parkinson's Disease. Journal of Parkinson s Disease. 4(3). 361–373. 36 indexed citations

13.

Oertel, Wolfgang H., Axel Bauer, Werner Cassel, et al.. (2014). Effect Of Rotigotine Transdermal System On Nocturnal Blood Pressure Changes Associated With Periodic Limb Movements During Sleep In Patients With Restless Legs Syndrome (P5.268). Neurology. 82(10_supplement). 1 indexed citations

14.

Trenkwalder, Claudia, Bryan Kies, Péter Diószeghy, et al.. (2012). Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: Results from a 1-year, open-label extension of the RECOVER study. Research Portal (King's College London). 2(2). 79–85. 14 indexed citations

15.

Ghys, L., Erwin Surmann, John Whitesides, & Babak Boroojerdi. (2011). Effect of rotigotine on sleep and quality of life in Parkinson's disease patients:post hocanalysis of RECOVER patients who were symptomatic at baseline. Expert Opinion on Pharmacotherapy. 12(13). 1985–1998. 33 indexed citations

16.

Kim, Han‐Joon, Beom S. Jeon, Won Yong Lee, et al.. (2011). Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurology. 11(1). 100–100. 16 indexed citations

17.

Trenkwalder, Claudia, Bryan Kies, Monika Rudzińska, et al.. (2010). Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER). Movement Disorders. 26(1). 90–99. 326 indexed citations

18.

Krauss, Gregory L., Elinor Ben‐Menachem, Rūta Mameniškienė, et al.. (2009). Intravenous lacosamide as short‐term replacement for oral lacosamide in partial‐onset seizures. Epilepsia. 51(6). 951–957. 63 indexed citations

19.

Trenkwalder, C., К. Ray Chaudhuri, Tim Anderson, et al.. (2009). P2.170 Effect of rotigotine on control of early morning motor function and sleep quality in subjects with idiopathic Parkinson's disease. Parkinsonism & Related Disorders. 15. S136–S136. 2 indexed citations

20.

Biton, Victor, et al.. (2007). Intravenous lacosamide as replacement for oral lacosamide in patients with partial‐onset seizures. Epilepsia. 49(3). 418–424. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact